Vland Biotech(SH:603739) Dong Jian Yan Bao·2025-11-05 13:13Group 1: Report General Information - The report is about a research on Weilan Biology in the agricultural, livestock, and fishery industry on November 5, 2025 [1][2][17] Group 2: Research Participants - The research was participated by investors through online questions [2] - The company's reception staff included the chairman and general manager Chen Gang, director and financial controller Qiao Piyuan, board secretary Jiang Yong, and independent directors Lin Yingtin and Wang Jing [17] Group 3: Company's Development Strategy - The company focuses on the biological industry, aiming to become a world - class high - tech biological enterprise. It will form a new development pattern of "one body with two wings", building an industrial biological platform company driven by technological innovation and globalization [24] - The company adheres to technological innovation as the core strategy and has launched the "ecological innovation" strategy, building an open - innovation ecosystem [24] - The company takes global layout as an important strategy, aiming to increase the proportion of overseas revenue and expand into key regions like Southeast Asia and Africa [25][26] Group 4: Q3 Financial Performance - In Q3 2025, the company's operating income was 363.5997 million yuan, a year - on - year increase of 8.09% due to product sales structure adjustment; the net profit attributable to the parent was 35.0628 million yuan, a year - on - year increase of 205.02% due to the recognition of income from cooperation partners [26] Group 5: Technical Advantages in Animal Health - The company builds an "industry + service" comprehensive empowerment platform in the animal health field, providing systematic solutions [27] - The VLAND - PCP customized enzyme program has a database covering over a hundred feed ingredients, improving feed conversion efficiency and livestock growth performance [27] Group 6: R & D Investment and Progress - In the first three quarters of 2025, the company's R & D investment was 100.2386 million yuan, accounting for 9.87% of operating income, a year - on - year increase of 23.29% [28] - The company has 6 technology centers and 2 key laboratories, adopting a "dual - leadership" management model and an IPD system for R & D management [29][30] - The company cooperates with over 20 universities and research institutes and 60 large - and medium - sized production enterprises for R & D [30] Group 7: Microbial Technology in Environmental Protection - The company established the Weilan Saide Environmental Microbial Laboratory, applying microbial technology to environmental protection, but the business revenue accounts for a relatively small proportion [31]